Page 34 - TD-3-3
P. 34
Tumor Discovery Adjuvant immunotherapy in high-risk melanoma
Suppl):LBA9503-LBA9503. 2022;157(4):335-335.
doi: 10.1200/jco.2023.41.17_suppl.lba9503 doi: 10.1001/jamasurg.2021.7554
31. Menzies AM, Amaria RN, Rozeman EA, et al. Pathological 33. Luke JJ, Rutkowski P, Queirolo P, et al. Pembrolizumab
response and survival with neoadjuvant therapy in versus placebo as adjuvant therapy in completely
melanoma: A pooled analysis from the International resected stage IIB or IIC melanoma (KEYNOTE-716):
neoadjuvant melanoma consortium (INMC). Nat Med. A randomised, double-blind, phase 3 trial. Lancet.
2021;27(2):301-309. 2022;399(10336):1718-1729.
doi: 10.1038/s41591-020-01188-3 doi: 10.1016/s0140-6736(22)00562-1
32. Reijers IL, Rawson RV, Colebatch AJ, et al. Representativeness 34. Johnson R, Atkinson V, Bhave P, et al. Management of resected
of the index lymph node for total nodal basin in pathologic stage III/IV melanoma with adjuvant immunotherapy. J Clin
response assessment after Neoadjuvant checkpoint inhibitor Oncol. 2021;39:9571-9571.
therapy in patients with stage III melanoma. JAMA Surg. doi: 10.1200/JCO.2021.39.15_suppl.9571
Volume 3 Issue 3 (2024) 10 doi: 10.36922/td.3143
